Tiffany Chai is a Venture Scientist, with responsibility for due diligence of investment opportunities on the Synapto Ventures portfolio, as well providing strategic and financial recommendation for fundraising.
Tiffany has a unique blend of scientific expertise, industry experience, and operational knowledge. She began her career at Duke-NUS Medical School, where she worked in the Department of Cancer and Stem Cell Biology. During her time there, she focused on understanding the molecular mechanisms that drive cancer progression and drug resistance, as well as identifying potential treatments for cancer. Her work resulted in multiple scientific publications and research grant.
Building on her scientific experience, Tiffany transitioned to the biopharmaceutical industry, joining WuXi AppTec in the Advanced Therapies Unit. As a bioprocessing scientist, she gained hands-on experience in the production of viral vector for gene therapy applications. Her involvement in client projects enhanced her understanding of bringing scientific discoveries into practical applications, enabling her to bridge the gap between cutting-edge research and real-world solutions.
In addition to her academia research and bioprocessing expertise, Tiffany has been deeply involved in laboratory operations. She worked closely with local and overseas stakeholders to facilitate technology transfer processes, managing laboratory resources and ensuring that all activities meet the regulatory compliance. Her operational acumen has played a key role in enhancing efficiency and driving successful outcomes to meet operational objectives.
Tiffany holds a PhD in Biochemistry from National University of Singapore.
